Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03496467 · ClinicalTrials.gov registry record · Phase 2
Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract
A Phase 2 study of Pain and Inflammation, sponsored by Mati Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 3
- Study locations
NCT03496467: Completed Phase 2 study of Pain and Inflammation, sponsored by Mati Therapeutics.
NCT03496467 is a Phase 2 study of Pain and Inflammation that has completed, run by Mati Therapeutics. The registered enrollment target is 56 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03496467, a Phase 2 study of Pain and Inflammation, has completed, sponsored by Mati Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. One (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two treatment groups: N-PPDS or p-PPDS, which are inserted in the lower punctum of the subject's scheduled surgical eye. All plugs will remain in the study subject's lower punctum for a period of 2 weeks following cataract surgery.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Nepafenac PPDS
- COMBINATION_PRODUCT Placebo PPDS
Study Locations (3)
Kentucky
- Cincinnati Eye Institute-Edgewood - Edgewood
New York
- Ophthalmic Consultants of Long Island - Garden City
South Carolina
- Kerry Solomon, MD - Mt. Pleasant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2018-03-05 |
| Est. Completion | 2018-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03496467
The ClinicalTrials.gov registry entry for NCT03496467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (82% lower). The listed sponsor is Mati Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Nepafenac PPDS is the first listed.
NCT03496467 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Kentucky, New York, South Carolina.
Frequently Asked Questions
What is clinical trial NCT03496467 about?
NCT03496467 is a clinical study titled "Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract". This is a Phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. One (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two treatment groups: N-PPDS or p-PPDS, which are inserted in the lower punctum of...
What is the current status of trial NCT03496467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2018-03-05. Estimated completion is 2018-12-17.
What conditions does trial NCT03496467 study?
This clinical trial studies the following conditions: Pain, Inflammation.
What interventions are being tested in trial NCT03496467?
The interventions under investigation include: Nepafenac PPDS (COMBINATION_PRODUCT), Placebo PPDS (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03496467?
This trial is sponsored by Mati Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03496467 being conducted?
This trial has 3 study locations across Kentucky, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Neural Correlates of Hypoalgesia Driven by Observation
RECRUITING · Phase 2
-
Cannabis for Palliative Care in Cancer
RECRUITING · Phase 2
-
Pain After Buffered Vs Non Buffered Articaine
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.